Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly ...

Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 "Bringing Alzheimer's disease treatment options to ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

FOX 9 caught up with a Minnesota woman undergoing a new Alzheimer’s treatment which is showing promise in slowing cognitive ...

Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt, ...

Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 INDIANAPOLIS, Dec. 17, 2024 /PRNewswire/ -- Eli Lilly and ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...